Trichomoniasis and HIV interactions: A review

Sexually Transmitted Infections

Volumn 89, Issue 6, 2013, Pages 426-433

  Kissinger, Patricia ^a   Adamski, Alys ^a  

^a TULANE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BETA DEFENSIN; METRONIDAZOLE; NEVIRAPINE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TINIDAZOLE;

CELLULAR IMMUNITY; CONDOM; DRUG EFFICACY; HEALTH PROMOTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; INFORMATION RETRIEVAL; LACTOBACILLUS; MIXED INFECTION; MUCOSAL IMMUNITY; PRIORITY JOURNAL; REINFECTION; REVIEW; SAFE SEX; SEROCONVERSION; SEX RATIO; SEXUAL HEALTH; SEXUALLY TRANSMITTED DISEASE; SINGLE DRUG DOSE; TREATMENT FAILURE; TRICHOMONIASIS; UNPROTECTED SEX; VAGINAL LAVAGE; VIRUS LOAD; VIRUS SHEDDING;

HIV; PUBLIC HEALTH; TRANSMISSION DYNAMICS; TREATMENT; TRICHOMONAS;

COINFECTION; FEMALE; HIV INFECTIONS; HUMANS; TRICHOMONAS INFECTIONS; TRICHOMONAS VAGINALIS;

EID: 84884533431     PISSN: 13684973     EISSN: 14723263     Source Type: Journal    
DOI: 10.1136/sextrans-2012-051005     Document Type: Review

References (79)

1. World Health Organization W. Prevalence and incidence of selected sexually transmitted infections, Chlamydia trachomatis, Neisseria gonorrhoeae, syphlis and Trichomonas vaginalis: methods and results used by WHO to generate 2005 estimates. Geneva, Switzerland, 2011. http://whqlibdoc.who.int/ publications/2011/9789241502450-eng.pdf
2. Hobbs MM, Sena A, Swygard H, et al. Trichomons vaginalis and trichomoniasis. In: Holmes KK, Stamm WE, Piot P, et al. eds. Sexually transmitted diseases. 4th edn. New York: McGraw-Hill, 2008:771-94.
3. Sutton M, Sternberg M, Koumans EH, et al. The prevalence of Trichomonas vaginalis infection among reproductive-Age women in the United States, 2001- 2004. Clin Infect Dis 2007;45:1319-26. (Pubitemid 351411908)
4. Centers for Disease Control and P. HIV among African Americans. Atlanta: National Center for HIV/AIDS VH, STD, and TB Prevention, 2011.
5. Johnston VJ, Mabey DC. Global epidemiology and control of Trichomonas vaginalis. Curr Opin Infect Dis 2008;21:56-64.
6. Watson-Jones D, Mugeye K, Mayaud P, et al. High prevalence of trichomoniasis in rural men in Mwanza, Tanzania: results from a population based study. Sex Transm Infect 2000;76:355-62.
7. Klinger EV, Kapiga SH, Sam NE, et al. A Community-based study of risk factors for Trichomonas vaginalis infection among women and their male partners in Moshi urban district, northern Tanzania. Sex Transm Dis 2006;33:712-8. (Pubitemid 44832930)
8. Mostad SB, Overbaugh J, DeVange DM, et al. Hormonal contraception, vitamin a deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet 1997;350:922-7. (Pubitemid 27420529)
9. McClelland RS, Sangare L, Hassan WM, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis 2007;195:698-702.
10. Shafir SC, Sorvillo FJ, Smith L. Current issues and considerations regarding trichomoniasis and human immunodeficiency virus in African-Americans. Clin Microbiol Rev 2009; 22:37-45, Table of Contents
11. Cu-Uvin S, Ko H, Jamieson DJ, et al. Prevalence, incidence, and persistence or recurrence of trichomoniasis among human immunodeficiency virus (HIV)-positive women and among HIV-negative women at high risk for HIV infection. Clin Infect Dis 2002;34:1406-11. (Pubitemid 34507952)
12. Magnus M, Clark R, Myers L, et al. Trichomonas vaginalis among HIV-Infected women: are immune status or protease inhibitor use associated with subsequent T. vaginalis positivity? Sex Transm Dis 2003;30:839-43. (Pubitemid 37386215)
13. Miller M, Liao Y, Wagner M, et al. HIV, the clustering of sexually transmitted infections, and sex risk among African American women who use drugs. Sex Transm Dis 2008;35:696-702.
14. Moodley P, Wilkinson D, Connolly C, et al. Influence of HIV-1 coinfection on effective management of abnormal vaginal discharge. Sex Transm Dis 2003; 30:1-5. (Pubitemid 36071076)
15. Watts DH, Springer G, Minkoff H, et al. The occurrence of vaginal infections among HIV-infected and high-risk HIV-uninfected women: longitudinal findings of the women's interagency HIV study. J Acquir Immune Defic Syndr 2006; 43:161-8. (Pubitemid 44454809)
16. Kalichman SC, Pellowski J, Turner C. Prevalence of sexually transmitted co-infections in people living with HIV/AIDS: systematic review with implications for using HIV treatments for prevention. Sex Transm Infect 2011;87:183-90.
17. Laga M, Manoka A, Kivuvu M, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. Aids 1993;7:95-102. (Pubitemid 23069039)
18. Laga M, Alary M, Nzila N, et al. Condom promotion, sexually transmitted diseases treatment, and declining incidence of HIV-1 infection in female Zairian sex workers. Lancet 1994;344:246-8.
19. Taha TE, Hoover DR, Dallabetta GA, et al. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. Aids 1998;12:1699-706. (Pubitemid 28418342)
20. Ghys PD, Diallo MO, Ettiegne-Traore V, et al. Effect of interventions to control sexually transmitted disease on the incidence of HIV infection in female sex workers. AIDS 2001;15:1421-31. (Pubitemid 32662294)
21. Myer L, Denny L, de Souza M, et al. Distinguishing the temporal association between women's intravaginal practices and risk of human immunodeficiency virus infection: a prospective study of South African women. Am J Epidemiol 2006;163:552-60.
22. Kleinschmidt I, Rees H, Delany S, et al. Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort. Contraception 2007;75:461-7. (Pubitemid 46764303)
23. Van Der Pol B, Kwok C, Pierre-Louis B, et al. Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis 2008;197:548-54. (Pubitemid 351321532)
24. Mavedzenge SN, Pol BV, Cheng H, et al. Epidemiological synergy of Trichomonas vaginalis and HIV in Zimbabwean and South African women. Sex Transm Dis 2010;37:460-6.
25. Delany-Moretlwe S, Nanoo A, Nagpal A, et al. Risk factors associated with HIV acquisition: a comparative analysis of older and younger women who participated in the MDP301 trial in Johannesburg. Sex Transm Infect 2011;87: A179-80.
26. Vandepitte J, Weiss HA, Bukenya J, et al. Alcohol use, mycoplasma genitalium, and other STIs sssociated with HIV incidence among women at high risk in Kampala, Uganda. J Acquir Immune Defic Syndr 2013;62:119-26.
27. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000;342:921-9. (Pubitemid 30177052)
28. Hester RA, Kennedy SB. Candida infection as a risk factor for HIV transmission. J Womens Health (Larchmt) 2003;12:487-94. (Pubitemid 36874090)
29. Hughes JP, Baeten JM, Lingappa JR, et al. Determinants of per-coital-Act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis 2012;205:358-65.
30. Sorvillo F, Smith L, Kerndt P, et al. Trichomonas vaginalis, HIV, and African-Americans. Emerg Infect Dis 2001;7:927-32.
31. Quinlivan EB, Patel SN, Grodensky CA, et al. Modeling the impact of Trichomonas vaginalis infection on HIV transmission in HIV-infected individuals in medical care. Sex Transm Dis 2012;39:671-7.
32. Chesson HW, Blandford JM, Pinkerton SD. Estimates of the annual number and cost of new HIV infections among women attributable to trichomoniasis in the United States. Sex Transm Dis 2004;31:547-51. (Pubitemid 39122137)
33. Fastering D KP. Vaginal Shedding of HIV-1 RNA in the presence of Trichomonas vaginalis and bacterial vaginosis. 19th International AIDS Conference. Washington D.C. USA, 2012.
34. Baggaley RF, White RG, Hollingsworth TD, et al. Heterosexual HIV-1 infectiousness and antiretroviral use: systematic review of prospective studies of discordant couples. Epidemiology 2013;24:110-21.
35. Clemetson DB, Moss GB, Willerford DM, et al. Detection of HIV DNA in cervical and vaginal secretions. Prevalence and correlates among women in Nairobi, Kenya. JAMA 1993;269:2860-4. (Pubitemid 23157009)
36. Ghys PD, Fransen K, Diallo MO, et al. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote d'Ivoire. AIDS 1997;11:F85-93. (Pubitemid 27421168)
37. John GC, Nduati RW, Mbori-Ngacha D, et al. Genital shedding of human immunodeficiency virus type 1 DNA during pregnancy: association with immunosuppression, abnormal cervical or vaginal discharge, and severe vitamin A deficiency. J Infect Dis 1997;175:57-62. (Pubitemid 27020824)
38. Hobbs MM, Kazembe P, Reed AW, et al. Trichomonas vaginalis as a cause of urethritis in Malawian men. Sex Transm Dis 1999;26:381-7. (Pubitemid 29372769)
39. Kovacs A, Wasserman SS, Burns D, et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001;358:1593-601. (Pubitemid 33101909)
40. Spinillo A, Debiaggi M, Zara F, et al. Factors associated with nucleic acids related to human immunodeficiency virus type 1 in cervico-vaginal secretions. BJOG : an international journal of obstetrics and gynaecology 2001;108:634-41. (Pubitemid 33646506)
41. Price MA, Zimba D, Hoffman IF, et al. Addition of treatment for trichomoniasis to syndromic management of urethritis in Malawi: a randomized clinical trial. Sex Transm Dis 2003;30:516-22. (Pubitemid 36667033)
42. Cu-Uvin S, Snyder B, Harwell JI, et al. Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months. J Acquir Immune Defic Syndr 2006;42:584-7. (Pubitemid 44162427)
43. Neely MN, Benning L, Xu J, et al. Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007;44:38-42. (Pubitemid 46052218)
44. Kissinger P, Amedee A, Clark RA, et al. Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis 2009;36:11-6.
45. Paz-Bailey G, Sternberg M, Puren AJ, et al. Determinants of HIV type 1 shedding from genital ulcers among men in South Africa. Clin Infect Dis 2010;50:1060-7.
46. Tanton C, Weiss HA, Le Goff J, et al. Correlates of HIV-1 genital shedding in Tanzanian women. PloS one 2011;6:e17480.
47. Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-Analysis. Sex Transm Dis 2008;35:946-59.
48. Rottingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted disease and HIV: how much really is known? Sex Trans Dis 2001;20:579-97. (Pubitemid 32937567)
49. Anderson BL, Firnhaber C, Liu T, et al. Effect of trichomoniasis therapy on genital HIV viral burden among African women. Sex Transm Dis 2012;39:638-42.
50. Wang CC, McClelland RS, Reilly M, et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis 2001;183:1017-22. (Pubitemid 32230948)
51. Masese LN, Graham SM, Gitau R, et al. A prospective study of vaginal trichomoniasis and HIV-1 shedding in women on antiretroviral therapy. BMC infectious diseases 2011;11:307.
52. Thurman AR, Doncel GF. Innate immunity and inflammatory response to Trichomonas vaginalis and bacterial vaginosis: relationship to HIV acquisition. American Journal of Reproductive Immunology 2011;65:89-98.
53. Hawes SE, Hillier SL, Benedetti J, et al. Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections. J Infect Dis 1996;174:1058-63. (Pubitemid 26357470)
54. Brotman RM, Bradford LL, Conrad M, et al. Association between Trichomonas vaginalis and vaginal bacterial community composition among reproductive-Age women. Sex Transm Dis 2012;39:807-12.
55. Baeten JM, Hassan WM, Chohan V, et al. Prospective study of correlates of vaginal Lactobacillus colonisation among high-risk HIV-1 seronegative women. Sex Transm Infect 2009;85:348-53.
56. Klebanoff SJ, Coombs R Viricidal effect of Lactobacillus acidophilus on human immunodeficiency virus type 1: possible role in heterosexual transmission. The Journal of experimental medicine 1991;174:289-92.
57. Hladik F, Hope TJ. HIV infection of the genital mucosa in women. Current HIV/AIDS reports 2009;6:20-8.
58. Swygard H, Sena AC, Hobbs MM, et al. Trichomoniasis: clinical manifestations, diagnosis and management. Sex Transm Infect 2004;80:91-5. (Pubitemid 38496831)
59. McNeely TB, Dealy M, Dripps DJ, et al. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. The Journal of clinical investigation 1995;96:456-64.
60. Draper D, Donohoe W, Mortimer L, et al. Cysteine proteases of Trichomonas vaginalis degrade secretory leukocyte protease inhibitor. J Infect Dis 1998;178:815-9. (Pubitemid 28397230)
61. Cauci S, Culhane JF. Modulation of vaginal immune response among pregnant women with bacterial vaginosis by Trichomonas vaginalis Chlamydia trachomatis Neisseria gonorrhoeae, and yeast. Am J Obstet Gynecol 2007;196:133 e1-7.
62. Fichorova RN, Trifonova RT, Gilbert RO, et al. Trichomonas vaginalis lipophosphoglycan triggers a selective upregulation of cytokines by human female reproductive tract epithelial cells. Infection and immunity 2006;74:5773-9. (Pubitemid 44484563)
63. Shattock RJ, Haynes BF, Pulendran B, et al. Improving defences at the portal of HIV entry: mucosal and innate immunity. PLoS medicine 2008;5:e81.
64. Schwebke JR, Desmond RA. A randomized controlled trial of partner notification methods for prevention of trichomoniasis in women. Sex Transm Dis 2010;37:392-6.
65. Kissinger P, Secor WE, Leichliter JS, et al. Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women. Clin Infect Dis 2008;46:994-9. (Pubitemid 351589863)
66. Krashin JW, Koumans EH, Bradshaw-Sydnor AC, et al. Trichomonas vaginalis prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population. Sex Transm Dis 2010;37:440-4.
67. Tidwell BH, Lushbaugh WB, Laughlin MD, et al. A double-blind placebo-controlled trial of single-dose intravaginal versus single-dose oral metronidazole in the treatment of trichomonal vaginitis. J Infect Dis 1994;170:242-6. (Pubitemid 24186456)
68. Spence MR, Harwell TS, Davies MC, et al. The minimum single oral metronidazole dose for treating trichomoniasis: a randomized, blinded study. Obstet Gynecol 1997;89:699-703. (Pubitemid 27195034)
69. duBouchet L, Spence MR, Rein MF, et al. Multicenter comparison of clotrimazole vaginal tablets, oral metronidazole, and vaginal suppositories containing sulfanilamide, aminacrine hydrochloride, and allantoin in the treatment of symptomatic trichomoniasis. Sex Transm Dis 1997;24:156-60. (Pubitemid 27123191)
70. Gatski M, Mena L, Levison J, et al. Patient-delivered partner treatment and Trichomonas vaginalis repeat infection among human immunodeficiency virus-infected women. Sex Transm Dis 2010;37:502-5.
71. Niccolai LM, Kopicko JJ, Kassie A, et al. Incidence and predictors of reinfection with Trichomonas vaginalis in HIV-infected women. Sex Transm Dis 2000;27:284-8. (Pubitemid 30252421)
72. Gatski M, Martin DH, Levison J, et al. The influence of bacterial vaginosis on the response to Trichomonas vaginalis treatment among HIV-infected women. Sex Transm Infect 2011;87:205-8.
73. Balkus JE, Richardson BA, Kiarie J, et al. Nevirapine-based antiretroviral therapy is associated with an increased risk of treatment failure of single-dose 2g oral metronidazole for trichomonas vaginalis infection. Infectious Diseases Society of Obstetrics and Gynecology. Whistler, Canada, 2012.
74. Kissinger P, Adamski A, Clark RA, et al. Does antiretroviral therapy interfere with the treatment of Trichomonas vaginalis among HIV+ women? Sex Trans Dis 2013 (in press).
75. Jain A, Lal N, Kumar L, et al. Novel trichomonacidal spermicides. Antimicrob Agents Chemother 2011;55:4343-51.
76. Cudmore SL, Garber GE. Prevention or treatment: the benefits of Trichomonas vaginalis vaccine. Journal of infection and public health 2010;3:47-53.
77. Sobel JD. What's new in bacterial vaginosis and trichomoniasis? Infectious disease clinics of North America 2005;19:387-406.
78. Weiss HA, Dickson KE, Agot K, et al. Male circumcision for HIV prevention: current research and programmatic issues. Aids 2010;24 Suppl 4:S61-9.
79. Mehta SD, Moses S, Agot K, et al. Adult male circumcision does not reduce the risk of incident Neisseria gonorrhoeae, Chlamydia trachomatis, or Trichomonas vaginalis infection: results from a randomized, controlled trial in Kenya. J Infect Dis 2009;200:370-8. Diseases